Immunovia AB (OSTO:IMMNOV) Debt-to-Asset : 0.02 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Debt-to-Asset?

Immunovia AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr1.50 Mil. Immunovia AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. Immunovia AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was kr63.10 Mil. Immunovia AB's debt to asset for the quarter that ended in Sep. 2024 was 0.02.

Immunovia AB Debt-to-Asset Historical Data

The historical data trend for Immunovia AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Debt-to-Asset Chart

Immunovia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.09

0.05

0.07

0.13

0.04

Immunovia AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.18	0.04	0.12	0.15	0.02

Competitive Comparison of Immunovia AB's Debt-to-Asset

For the Diagnostics & Research subindustry, Immunovia AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovia AB's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Debt-to-Asset falls into.

Immunovia AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immunovia AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.499	+	1.787)	/	98.681
	=	0.04

Immunovia AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.496	+	0)	/	63.099
	=	0.02

Immunovia AB (OSTO:IMMNOV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immunovia AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0G8X:UK

Address

Medicon Village, Scheelevagen 8, Lund, SWE, 223 63

Website

https://www.immunovia.com

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines